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Duration of rheumatoid arthritis and the
risk of developing interstitial lung
disease
To the Editor:
Rheumatoid arthritis is an autoimmune disease that classically presents as a symmetrical inflammatory
polyarthritis. Extra-articular manifestations are prevalent, with the lungs being the most common site [1],
and interstitial lung disease (ILD) being the most severe form of pulmonary involvement. In some studies,
the median survival of patients with rheumatoid arthritis and a usual interstitial pneumonia (UIP) pattern
on high-resolution computed tomography (HRCT) is around 3 years (similar to that in idiopathic
pulmonary fibrosis (IPF) [2, 3]); however, in other studies, median survival is >7 years [4, 5]. When
present, ILD accounts for 10–20% of all deaths in rheumatoid arthritis [6].
There have been many reported risk factors for ILD in patients with rheumatoid arthritis, including male
sex, the severity of rheumatoid arthritis and cigarette smoking [7–9]. High titres of circulating
autoantibodies (rheumatoid factor, anti-cyclic citrullinated (CCP) antibodies) may also predict ILD [10, 11].
Rheumatoid arthritis–interstitial lung disease (RA-ILD) onset has previously been shown to occur in the
6th or 7th decade [12], prompting many to think of ILD as a late-occurring phenomenon in rheumatoid
arthritis. In a single-centre, retrospective study of 582 subjects with rheumatoid arthritis, of which only 46
had RA-ILD, every decade increase in age at the time of rheumatoid arthritis diagnosis was associated
with a 41% increased risk of RA-ILD [9]. Though it is occasionally reported in the literature that a longer
duration of rheumatoid arthritis is a risk factor for ILD, there are no supporting data [13–15].
The aim of this retrospective, single-centre study, was to evaluate duration of rheumatoid arthritis as a risk
factor for ILD and to determine whether duration of rheumatoid arthritis and age correlated with a
radiological pattern of nonspecific interstitial pneumonia (NSIP) or UIP. Our institutional research
database was queried for all subjects with a diagnosis of RA-ILD, with radiological UIP or NSIP pattern,
between 2000 and 2014 (n=137). Subjects without sufficient data to determine a date of ILD diagnosis
were excluded, with the final cohort including 121 subjects. The date of ILD diagnosis was defined as the
earlier between the first report of ILD on imaging, the first date an outside pulmonologist confirmed a
diagnosis of ILD or the first visit with an ILD specialist. A “concomitant” diagnosis of rheumatoid
arthritis and ILD is defined as both conditions being diagnosed within a year of each other to account for
the time from symptom onset to diagnosis. For initial analysis, all 121 patients in the cohort were
included. In assessment of ILD diagnosis concomitant to, or after rheumatoid arthritis diagnosis, patients
with preceding ILD diagnoses were excluded. Each subject’s HRCT scan was independently reviewed by
two expert thoracic radiologists ( JC and SH) with all disagreements resolved through discussions until
consensus was reached. Scans were classified as showing a pattern of UIP (RA-UIP, including both “UIP”
and “probable UIP”) or NSIP (RA-NSIP). Pulmonary function tests performed within 6 months of ILD
diagnosis were recorded. This cohort has been previously reported on [4].
Statistical analysis was performed use SAS statistical software, Version 9.3 (SAS, Inc.; Cary, NC, USA). For
initial analysis, all 121 patients in the cohort were included. In certain analyses, we excluded subjects
diagnosed with ILD >1 year prior to the diagnosis of rheumatoid arthritis. We assessed time-to-ILD using
the product-limit method, displayed results using Kaplan–Meier curves and compared curves using the log
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FIGURE 1 a) Baseline characteristics of cohort. Age at interstitial lung disease (ILD) diagnosis in rheumatoid arthritis (RA) patients. Histograms
demonstrating number of patients at a given age (batched on 5-year intervals) at time of ILD diagnosis in b) all RA-ILD patients, and divided by
high-resolution computed tomography (HRCT) radiological pattern of c) usual interstitial pneumonia (UIP) and d) nonspecific interstitial
pneumonia (NSIP). Kaplan–Meier curves showing the time to development of ILD after the diagnosis of RA in e) all RA-ILD patients, and divided by
HRCT radiological pattern of f ) UIP and g) NSIP. Duration of RA at time of ILD diagnosis. Histograms demonstrating number of patients at a given
RA duration, defined as years from diagnosis of RA (batched on 5-year intervals) at time of ILD diagnosis in h) all RA-ILD patients, and divided by
HRCT radiological pattern of i) UIP and j) NSIP. CCP: cyclic citrullinated antibodies; RF: rheumatoid factor; FVC: forced vital capacity;
DLCO: diffusing capacity of the lung for carbon monoxide. *: p<0.05.
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rank test. We used Cox proportional hazards to analyse time-to-ILD while controlling for potentially
influential and confounding variables. We did not use selection methods but chose to include in our
models clinically relevant potential confounders. We considered p<0.05 to represent statistical significance.
As shown in figure 1a, the mean age at diagnosis of RA-ILD in our study was 63 years and did not differ
between UIP and NSIP. Subjects were more likely to be male (51%) and current or former smokers (61%).
When divided by HRCT pattern, those with UIP were more likely to have smoked and had higher
rheumatoid factor titres than subjects with NSIP. Treatments were similar between the two groups.
Compared to subjects with RA-NSIP, those with RA-UIP were diagnosed with rheumatoid arthritis at an
older age (53.5±16 versus 45.6±14 years, p=0.01). After accounting for sex and smoking, this difference
remained significant (p=0.001).
The range in age at diagnosis of ILD was similar between RA-UIP and RA-NSIP (figure 1b–d). A
significant percentage of patients had ILD either predating (10%, n=12) or concomitant with (17%, n=20)
the diagnosis of rheumatoid arthritis. 49% of subjects developed ILD either before or within 5 years of the
rheumatoid arthritis diagnosis and 67% of subjects developed ILD either before or within 13 years of being
diagnosed with rheumatoid arthritis.
To evaluate the duration of rheumatoid arthritis prior to the diagnosis of ILD, only those subjects whose
ILD diagnosis was “concomitant” with or following the diagnosis of rheumatoid arthritis were analysed
(n=109) (figure 1e–g). The mean duration of rheumatoid arthritis before the diagnosis of ILD was
12.4 years. Compared to NSIP, UIP was diagnosed closer to the onset of rheumatoid arthritis (10.6 versus
18.3 years from diagnosis of rheumatoid arthritis, p=0.025, figure 1h–j). When controlling for cofounders
such as sex and smoking status, this difference remained significant (p=0.011). UIP was the ILD pattern
in 84% of patients whose ILD was diagnosed prior to or concomitant with rheumatoid arthritis. When
ILD was diagnosed 15 years after rheumatoid arthritis, patients were more likely to have NSIP than UIP
(p=0.039).
The development of ILD is a dreaded consequence of rheumatoid arthritis. Though there are established
risk factors, there are no good prediction models to help clinicians determine who with rheumatoid
arthritis will get ILD and when in the course of rheumatoid arthritis their ILD will develop. Our results
add to this field of study by shedding light on the age at time of ILD diagnosis and its relationship to the
time of rheumatoid arthritis diagnosis with respect to radiological ILD pattern.
Our study has limitations. This is a retrospective assessment of patients evaluated at a tertiary referral
centre and may not be representative of patients seen in a community pulmonary practice. We rely on the
time of clinical diagnosis of rheumatoid arthritis and ILD, and there is clear evidence that both synovitis
and interstitial lung abnormalities can be present for months or years prior to a clinical diagnosis of
rheumatoid arthritis or ILD. We did not analyse the impact of rheumatoid arthritis disease activity, which
may have impacted the timing, subtype and severity of the ILD diagnosis.
In conclusion, we found that the pattern of ILD in patients with rheumatoid arthritis depends on the age
of rheumatoid arthritis diagnosis and the duration between the diagnosis of rheumatoid arthritis and the
diagnosis of ILD. ILD diagnosis clusters around the time of rheumatoid arthritis diagnosis and has a mean
age of onset similar to that seen in IPF. We also found that smokers are more likely to develop a UIP
pattern of lung involvement, and the majority of subjects who developed ILD prior to rheumatoid arthritis
had a radiological UIP pattern. We are currently not able to predict who with rheumatoid arthritis will
develop ILD, but the knowledge that ILD clusters around the time of rheumatoid arthritis diagnosis with a
strong predilection for the 7th decade of life can aid clinicians in a timely diagnosis of ILD in those at
risk.
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